Mike Handley is successful life science business professional with over 18 years of cross-functional experience in drug/device commercialization, operations, mergers/acquisitions, regulatory/clinical affairs, venture formation/financing, market development and partnering/licensing. Mike has successfully assisted or led in the global commercialization of seventeen devices or drugs that account for over three billion dollars of sales annually. He has experience successfully leading management teams in a variety of capacities in high growth organizations and has secured millions of dollars in venture capital.
Currently, Mike is the Chief Executive Officer of CHD Bioscience, Inc. CHD Bioscience is a multi-product development-stage healthcare company that has created a technology platform for the prevention and treatment of infectious disease. In his current role, Mike is responsible for day-to-day operations, executing a profitable growth strategy, obtaining global product approvals, overseeing intellectual property strategy, product commercialization, business development and financing.
In addition to Symbios and CHD Bioscience, Mike also serves as a Board member to multiple life science companies and is assisting them with financing, growth and commercialization strategies. Mike is also a founding partner at the life science focused venture creation and finance firm Level 5 Partners LLC. Furthermore, Mike has also served in management roles at J&J, Vessix Vascular, Spectranetics and the senior management consulting firm Pittiglio Rabin Todd & McGrath (now PricewaterhouseCoopers).
Mike graduated cum laude from Colorado State University with Bachelor of Science degrees in Molecular Biology, Exercise Physiology and minors in Chemistry, and Neurobiology. Mike complemented his formal education by attending The Graziadio Business School at Pepperdine University Executive Management MBA Program.